Evidence map›Paper›PMID 38940353›Full record

ArticleOncology reports2024

SNAI2 enhances HPV‑negative cervical cancer cell dormancy by modulating u‑PAR expression and the activity of the ERK/p38 signaling pathway

Yuanhong Zhou, Yan Xie, Youzheng Luo, Shuling Wang, Qing Han, Qiang Liu

Abstract read
In one paragraph

Article in Oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. ITGA5 is overexpressed and promotes tumor progression through SNAI2 in OSCC.Frontiers in cell and developmental biology · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuanhong ZhouThe First College of Clinical Medical Science, China Three Gorges University/Yichang Central People's Hospital, Yichang, Hubei 443000, P.R. China.
Yan XieThe First College of Clinical Medical Science, China Three Gorges University/Yichang Central People's Hospital, Yichang, Hubei 443000, P.R. China.
Youzheng LuoThe First College of Clinical Medical Science, China Three Gorges University/Yichang Central People's Hospital, Yichang, Hubei 443000, P.R. China.
Shuling WangThe First College of Clinical Medical Science, China Three Gorges University/Yichang Central People's Hospital, Yichang, Hubei 443000, P.R. China.
Qing HanThe First College of Clinical Medical Science, China Three Gorges University/Yichang Central People's Hospital, Yichang, Hubei 443000, P.R. China.
Qiang LiuThe First College of Clinical Medical Science, China Three Gorges University/Yichang Central People's Hospital, Yichang, Hubei 443000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognosis of patients with human papillomavirus (HPV)‑negative cervical cancer is significantly worse than that of patients with HPV‑positive cervical cancer. Understanding the mechanisms of this is crucial for preventing disease evolution. In the present study, the GV367‑snail family transcriptional repressor 2 (SNAI2) lentiviral vector was constructed and transduced into C‑33A cells. Subsequently, the proliferation of tumor cells was detected using the Cell Counting Kit (CCK)‑8 method. Flow cytometry was used to analyze the cell cycle progression of tumor cells. The glucose consumption of tumor cells was detected using an oxidase assay, and the senescence of tumor cells was detected using beta‑galactosidase staining. The gene expression and the activity of p38 and ERK1/2 were detected using reverse transcription‑quantitative PCR and western blotting, respectively. The C‑33A‑SNAI2 cell line was successfully established. Compared with HeLa and C‑33A‑Wild cells, the proliferation and percentage of G0/G1‑phase cells in the C‑33A‑SNAI2 group were decreased, as detected by the CCK‑8 assay (100±0 vs. 239.1±58.3 vs. 39.7±20.1, P<0.01) and flow cytometry (34.0±7.1% vs. 46.2±10.6% vs. 61.3±5.3%, P<0.05). Compared with the HeLa group, the glucose consumption of the C‑33A‑Wild and C‑33A‑SNAI2 groups was significantly decreased (P<0.01). The results of beta‑galactosidase staining showed that the proportion of beta‑galactosidase‑positive cells in the C‑33A‑SNAI2 group was significantly decreased compared with the C‑33A‑Wild group (P<0.01). Upregulation of SNAI2 enhanced the increase in p21 expression, and the decrease in CDK1, urokinase plasminogen activator receptor (u‑PAR) and cyclin D1 expression in C‑33A cells compared with C‑33A‑Wild cells (P<0.05). In addition, the activities of p38, ERK1/2 and the phosphorylated (p)‑ERK1/2/p‑p38 ratio were decreased in the C‑33A‑SNAI2 group compared with the C‑33A‑Wild and HeLa groups (P<0.05). In conclusion, SNAI2 enhanced HPV‑negative cervical cancer C‑33A cell dormancy, which was characterized by G0/G1 arrest, by the downregulation of u‑PAR expression, and a decrease in the activity of the p‑ERK1/2 and p‑p38MAPK signaling pathways

Indexed as

Cell ProliferationGene Expression Regulation, NeoplasticSnail Family Transcription FactorsUterine Cervical NeoplasmsCell CycleCell Line, TumorCellular SenescenceFemaleHeLa CellsHumansMAP Kinase Signaling Systemp38 Mitogen-Activated Protein KinasesPapillomaviridaeReceptors, Urokinase Plasminogen Activatorp38 Mitogen-Activated Protein KinasesReceptors, Urokinase Plasminogen ActivatorSNAI2 protein, humanSnail Family Transcription FactorsdormancyERK/p‑38 signaling pathwayhuman papillomavirus‑negative cervical cancersnail family transcriptional repressor 2u‑PAR

Identifiers

PMID38940353
PMCPMC11228422

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.